Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Less than 2 weeks to go until the 13th annual ADMET event in London

Posted on: 27 Jun 18
Less than 2 weeks to go until the 13th annual ADMET event in London

SMi’s 13th annual ADMET conference is set to commence on the 9th and 10th July. This year's two-day event will bring together a global audience of DMPK scientists, toxicologists and senior industry thought-leaders dedicated to addressing the current market challenges, driven by an increased demand for screening and advances in technology.


Delegates will have the opportunity to network and hear insightful presentations and case studies on topics such as toxicology research strategies, modelling techniques, predictive pharmacology, pre-clinical DMPK studies, and many more.


Spotlight Presentations and Speakers:


“KPB – Strengths and limitations of compartmental modelling”, presented by Sheila-Annie Peters, Head, Translational Quantitative Pharmacology, Merck Serono. Peters will discuss the topics of the making of a successful drug candidate, as well as defining parameters in acute and chronic toxicity evaluations, drug safety testing, and cost-benefit assessments.


“Intracellular pharmacokinetics: Emerging opportunities for tailoring project support”, presented by Andreas Reichel, Vice President, Research Pharmacokinetics, Bayer. Reichel’s presentation will focus on the mechanisms that control intracellular drug concentrations, experimental approaches that are suitable to estimate unbound intracellular concentrations in selected cell types as well as their applicability to advance our understanding of intracellular drug-target interactions. In addition, sase studies will be shown to illustrate how the field of ICPK can offer novel opportunities that can be used to address key questions in drug discovery projects, thereby enhancing our understanding of the intracellular fate of drugs.


2018 Event Agenda:


Day 1: Opening keynote from AbbVie by Vice President, Global Pre-Clinical Safety, Senior Research Fellow, Eric Blomme on Novel technologies and computational tools in discovery toxicology: opportunities and challenges - his exclusive speaker Q&A interview is available on the event website’s download centre.


Day 2: Opening keynote from Vertex Pharmaceuticals by Peter Littlewood, Director of DMPK. The talk will discuss Human PK and dose predictions for compounds with challenging physiochemical profiles.


With the conference fast-approaching, places are now limited and potential attendees are urged to book soon at an exclusive price of £999 available for a limited time, to avoid disappointment. For the full agenda and list of expert speakers, download the latest brochure from the event website, as well as more exclusive free content including speaker interviews, at:


Interested in sponsoring, exhibiting or speaking at this event?

Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email


For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or



9th – 10th July 2018

Holiday Inn Kensington Forum, London, UK


Follow us @SMiPharm



---- END ----


About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

For more information:

Editor's Details

Simi Sapal
+44 (0)20 7827 6000

Last updated on: 27/06/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.